Cre/loxP system
C57BL/6-Tg(SLC18A3-cre)KMisa/MisaRbrc
C57BL/6-Tg(SLC18A3-cre)KMisa/MisaRbrc
Tg(SLC18A3-cre)KMisa, RBRC01515, is a transgenic Cre-driver mouse line, in which Cre expression is driven by the 11.3 kb human vesicular acetylcholine transporter (VAChT) promoter (Misawa et al., 2003). The lines showed restricted Cre expression in approximately one half (40-60%) of the postnatal somatic motor neurons and cholinergic neurons of the medial habenular nucleus. Transgenic expression was not observed in visceromotor or other central or peripheral cholinergic neurons. Cre expression began on approximately postnatal day 7 and reached at maximal levels by 5 weeks of age (earlier onset than Tg(SLC18A3-cre)AMisa, RBRC01516). Re-evaluation (Misawa et al., 2016) of the line by using subtype selective markers showed preferred Cre expression in slow-type motor neurons (S- and FR-type) innervating type I or IIa muscle fibers. To avoid confusion the common name of the line was changed from VAChT-Cre.Fast to VAChT-Cre.Early. Ref. Genesis, 54, 568-572 (2016).
Human vesicular acetylcholine transporter (SLC18A)genomic DNA, Phage P1 Cre recombinase, Encephalomyocarditis virus (EMCV) internal ribosomal entry site (ires), Jellyfish GFP cDNA
C（3〜6か月）
Kyoritsu College of Pharmacy
VAChT-Cre.Fast と VAChT-Cre.Slow では Cre の発現の Onset が異なる。 C57BL/6 Background (100%)、世代数：5
true
C (3-6 months)
<a href='https://brc.riken.jp/mus/pcr01515'>Genotyping protocol -PCR-</a>
条件を付加する。利用者は事前に寄託者の提供承諾書を得る。<br>本リソースを用いた研究は共同研究として成果発表を行なう。（2年間）
RBRC01515
Developed by Dr. Hidemi Misawa at Tokyo Metropolitan Institute for Neuroscience in 2003. The VaChT-Cre transgene was injected into the pronuclei of fertilized oocytes of C57BL/6 mice.
Fluorescent Proteins/lacZ System
Hidemi MISAWA
VAChT-Cre.Fast と VAChT-Cre.Slow では Cre の発現の Onset が異なる。C57BL/6 Background (100%)、世代数：5
VAChT-Cre.Early, (Formerly VAChT-Cre.Fast)
VAChT-Cre.Early, (Formerly VAChT-Cre.Fast)
三澤 日出巳
Necessary documents for ordering:<ol><li>Approval form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_6.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_d.docx">English</A>)</li><li>Order form (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_4.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_b.docx">English</A>)</li><li>Category I MTA: MTA for distribution with RIKEN BRC (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_5.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_c.docx">English</A>)</li><li>Acceptance of responsibility for living modified organism (<A HREF="https://mus.brc.riken.jp/ja/wp-content/uploads/form/form_7.docx">Japanese</A> / <A HREF="https://mus.brc.riken.jp/en/wp-content/uploads/form/form_g.docx">English</A>)</li><li>GFP Transfer License (<A HREF="https://web.brc.riken.jp/ja/method/link/gfp_conclude">Japanese</A> / <A HREF="https://web.brc.riken.jp/en/method/link/gfp_conclude">English</A>)<br>Please fill in the <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_a.doc">Schedule A</A>, and submit two signed copies to us together with two signed copies of RIKEN BRC's MTA. Please also read <A HREF="https://web.brc.riken.jp/en/wp-content/uploads/form/gfp_schedule_b.doc"> Schedule B</A>. </li></ol>
共立薬科大学
Tg(SLC18A3-cre)KMisa (RBRC01515) は、ヒトの小胞アセチルコリントランスポーターのプロモーター領域を含む11.3 kbのゲノム断片を用いたCre-driverラインである。脳と脊髄の体性運動ニューロン (約50%) 及び内側手綱核の一部で生後に Cre recombinase を発現する (Misawa et al., 2003)。前脳基底部、線条体、脳幹や自律神経など、その他のコリン作動性ニューロンにはCre発現は認められない。Cre発現は生後７日頃から始まり、数週間で最大レベルに達する (fast completion) 。これに対し、類似ラインであるTg(SLC18A3-cre)AMisa (RBRC01516) は最大レベルに達するのに数ヶ月を要する (slow completion)。運動神経のサブタイプマーカーを用いた再評価の結果 (Misawa et al., 2016)、赤筋 (遅筋; タイプI, IIa筋線維) に投射するSlow運動ニューロン (SおよびFRタイプ)にCre発現の選択性が認められた。このため、本マウス系統の名前 (通称名) をVAChT-Cre.FastからVAChT-Cre.Earlyに変更した。参考文献：Genesis, 54, 568-572 (2016).
backcross to C57BL/6 (Hemizygote x C57BL/6NJcl)
The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. A prior agreement for collaboration with the depositor should be required.